From Nasdaq: 2025-05-30 01:44:00

Roche announced promising 96-week data for fenebrutinib, showing no disability progression in patients with relapsing multiple sclerosis. Results from the Phase II FENopta study revealed low levels of disease activity for up to two years. Three Phase III trials for fenebrutinib in multiple sclerosis are ongoing, with initial data expected by the end of 2025. Roche’s Chief Medical Officer, Levi Garraway, highlighted that patients on fenebrutinib had an annualized relapse rate equivalent to one relapse every 17 years. These findings suggest potential benefits for MS patients. Visit rttnews.com for more health news updates.



Read more at Nasdaq: Roche Presents 96-week Data For Fenebrutinib